J Bacteriol Virol.  2012 Mar;42(1):1-8. 10.4167/jbv.2012.42.1.1.

Antimicrobial Resistance and Clones of Acinetobacter Species and Pseudomonas aeruginosa

• Lee JY
• Ko KS

• KMID: 1434767
• DOI: http://doi.org/10.4167/jbv.2012.42.1.1

Abstract

Antimicrobial resistance in bacteria is problematic in clinical settings and is a growing threat to public health. Multidrug-resistant and pandrug-resistant non-fermenters such as Acinetobacter spp. and Pseudomonas aeruginosa have recently emerged as a great concern worldwide. Particularly, the prevalence of carbapenem resistance in Acinetobacter spp. and P. aeruginosa is problematic, and emergence of polymyxin resistance is ominous. In this review, we discuss carbapenem and polymyxin resistance in Acinetobacter spp. and P. aeruginosa isolates and their major clones.

Keyword

Acinetobacter; Pseudomonas; Antimicrobial resistance; Carbapenems; Polymyxins

MeSH Terms

Acinetobacter
Bacteria
Carbapenems
Clone Cells
Polymyxins
Prevalence
Pseudomonas
Pseudomonas aeruginosa
Public Health
Carbapenems
Polymyxins

Reference

1. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008. 358:1271–1281.

2. Kapoor R. Acinetobacter infection. N Engl J Med. 2008. 358:2845–2846.

3. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007. 51:3471–3484.

4. Nemec A, Krizova L, Maixnerova M, van der Reijden TJ, Deschaght P, Passet V, et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res Microbiol. 2011. 162:393–404.

5. Park YK, Jung SI, Park KH, Kim DH, Choi JY, Kim SH, et al. Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years. J Med Microbiol. 2012. 61:71–79.

6. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis. 2006. 42:657–668.

7. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009. 22:582–610.

8. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005. 41:848–854.

9. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among Gram-negative bacilli as causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol. 2007. 45:3352–3359.

10. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007. 5:939–951.

11. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006. 43:S49–S56.

12. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother. 2004. 38:1449–1459.

13. Gilad J, Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs. 2008. 68:165–189.

14. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008. 52:813–821.

15. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005. 40:1333–1341.

16. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006. 6:589–601.

17. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006. 12:315–321.

18. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother. 2008. 52:351–352.

19. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006. 50:2946–2950.

20. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007. 60:1163–1167.

21. Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis. 2009. 15:1325–1327.

22. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2009. 15:980–982.

23. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004. 48:4606–4610.

24. Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, et al. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR Study 2009. Yonsei Med J. 2011. 52:793–802.

25. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011. 55:4943–4960.

26. Lee H, Ko KS, Song JH, Peck KR. Antimicrobial activity of doripenem and other carbapenems against Gram-negative pathogens from Korea. Microb Drug Resist. 2011. 17:37–45.

27. Baek JY, Ko KS, Kang CI, Song JH, Peck KR. In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates. Diagn Microbiol Infect Dis. 2011. 71:297–300.

28. Poole K. Pseudomonas aeruginosa: resistance to max. Front Microbiol. 2011. 2:65.

29. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006. 12:826–836.

30. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect. 2002. 8:321–331.

31. Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005. 49:3198–3202.

32. Gupta V. Metallo beta-lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin Investig Drugs. 2008. 17:131–143.

33. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a beta-lactamase gene, bla_GIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob Agents Chemother. 2004. 48:4654–4661.

34. Picão RC, Poirel L, Gales AC, Nordmann P. Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. Antimicrob Agents Chemother. 2009. 53:3908–3913.

35. Wang J, Zhou JY, Qu TT, Shen P, Wei ZQ, Yu YS, et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int J Antimicrob Agents. 2010. 35:486–491.

36. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009. 22:535–543.

37. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother. 2007. 59:786–790.

38. Lee JY, Song JH, Ko KS. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea. Microb Drug Resist. 2011. 17:299–304.

39. Gunn JS. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol. 2008. 16:284–290.

40. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol. 2004. 186:575–579.

41. Sun S, Negrea A, Rhen M, Andersson DI. Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother. 2009. 53:2298–2305.

42. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother. 2009. 53:3628–3634.

43. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010. 54:4971–4977.

44. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother. 2011. 55:3743–3751.

45. Abraham N, Kwon DH. A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa. FEMS Microbiol Lett. 2009. 298:249–254.

46. Barrow K, Kwon DH. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009. 53:5150–5154.

47. Muller C, Plésiat P, Jeannot K. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2011. 55:1211–1221.

48. Park YK, Choi JY, Shin D, Ko KS. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int J Antimicrob Agents. 2011. 37:525–530.

49. Dijkshoorn L, Aucken H, Gerner-Smidt P, Janssen P, Kaufmann ME, Garaizar J, et al. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol. 1996. 34:1519–1525.

50. Van Dessel H, Dijkshoorn L, van der Reijden T, Bakker N, Baauw A, van den Broek P, et al. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol. 2004. 155:105–112.

51. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010. 65:233–238.

52. Bartual SG, Seifert H, Hippler C, Luzon MA, Wisplinghoff H, Rodríguez-Valera F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005. 43:4382–4390.

53. Adams-Haduch JM, Onuoha EO, Bogdanovich T, Tian GB, Marschall J, Urban CM, et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacte baumanniir in the United States. J Clin Microbiol. 2011. 49:3849–3854.

54. Park YK, Jung SI, Park KH, Kim DH, Choi JY, Kim SH, et al. Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years. J Med Microbiol. 2012. 61:71–79.

55. Runnegar N, Sidjabat H, Goh HM, Nimmo GR, Schembri MA, Paterson DL. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a single institution over a 10-year period. J Clin Microbiol. 2010. 48:4051–4056.

56. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the bla_OXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2010. 16:35–40.

57. Fu Y, Zhou J, Zhou H, Yang Q, Wei Z, Yu Y, et al. Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. J Antimicrob Chemother. 2010. 65:644–650.

58. Snitkin ES, Zelazny AM, Montero CI, Stock F, Mijares L, Murray PR, et al. Genome-wide recombination drives diversification of epidemic strains of Acinetobacter baumannii. Proc Natl Acad Sci U S A. 2011. 108:13758–13763.

59. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol. 2004. 42:5644–5649.

60. O'Carroll MR, Syrmis MW, Wainwright CE, Greer RM, Mitchell P, Coulter C, et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J. 2004. 24:101–106.

61. Maatallah M, Cheriaa J, Backhrouf A, Iversen A, Grundmann H, Do T, et al. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One. 2011. 6:e25617.

62. Wiehlmann L, Wagner G, Cramer N, Siebert B, Gudowius P, Morales G, et al. Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 2007. 104:8101–8106.

63. Pirnay JP, Bilocq F, Pot B, Cornelis P, Zizi M, Van Eldere J, et al. Pseudomonas aeruginosa population structure revisited. PLoS One. 2009. 4:e7740.

64. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011. 35:736–755.

65. Edelstein M. Epidemic clones and dissemination of carbapenem resistance. 2011. ICAAC;173.

66. Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM, Walder M, et al. Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob Agents Chemother. 2010. 54:346–352.

67. Seok Y, Bae IK, Jeong SH, Kim SH, Lee H, Lee K. Dissemination of IMP-6 metallo-β-lactamase-producing Pseudomonas aeruginosa sequence type 235 in Korea. J Antimicrob Chemother. 2011. 66:2791–2796.

68. Lee JY, Lim MH, Heo ST, Ko KS. Repeated isolation of Pseudomonas aeruginosa isolates resistant to both polymyxins and carbapenems from one patient. Diagn Microbiol Infect Dis. 2000. (In press).

69. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996. 348:639–642.